Biotechnology

Q1 Report - Focused Execution Driving Growth

September 9, 2026 12:10 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Q1 (May 2026 - July 2026) (comparison figures are for the same period 2025/2026) Net sales amounted to KSEK 4,043(2,596), corresponding to an increase of 56%. In local currency, net sales increased by 57%. Operating Loss (EBIT) amounted to KSEK -20,334 (-19,334) including KSEK 2,200 (0) in restructuring costs. Cash flow from operating activities amounted to KSEK -16,100 (- 17,196). At...

Read more

Biovica Resolves on a Fully Guaranteed Rights Issue of SEK 29.2 Million

September 9, 2026 12:05 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - INSIDE INFORMATION: The board of directors of Biovica International AB (publ) ("Biovica" or the "Company") has today resolved, subject to subsequent approval by an extraordinary general meeting, to carry out a new share issue of B-shares of approximately SEK 29.2 million with preferential rights for the Company's existing shareholders (the "Rights Issue"). The subscription price has...

Read more

Notice of Extra General Meeting in Biovica International AB

September 9, 2026 12:00 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the extra general meeting to be held on Wednesday 30 September 2026, at 14:30 CEST at Baker McKenzie Advokatbyrå's office at Mäster Samuelsgatan 17, 111 44, in Stockholm. Right to attend and notification Shareholders who wish to attend the extra general meeting must: i. on the...

Read more

BrYet Announces AIFA Approval of First-In-Kind cGMP Manufacturing Line for ML-016, Enabling Imminent Clinical Supply to Australia

September 9, 2026 8:35 AM

BrYet US, Inc. ("BrYet"), a biotechnology innovator focused on developing potentially curative therapies for advanced cancers, today announced AIFA approval of a first-in-kind cGMP manufacturing line for ML-016, the company's lead clinical-stage cancer therapeutic. AIFA is the national public body that regulates medicines for human use in Italy, where BrYet's manufacturing subsidiary is located. BrYet logo. / Source: BrYet US, Inc. (EZ Newswire)...

Read more

Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers

September 9, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has completed formal qualification to become a supplier for five in-vitro diagnostics (IVD) manufacturers ("Dx Test-Makers"). Each of these five Dx Test-Makers are considered to be one of the ten largest such companies by revenues, and Microbix is pleased to have successfully completed their supplier audit &...

Read more

BrYet Announces AIFA Approval of First-In-Kind cGMP Manufacturing Line for ML-016, Enabling Imminent Clinical Supply to Australia

September 9, 2026 12:00 AM

BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on developing potentially curative therapies for advanced cancers - today announced AIFA approval of a first-in-kind cGMP manufacturing line for ML-016, the company's lead clinical-stage cancer therapeutic. AIFA is the national public body that regulates medicines for human use in Italy, where BrYet's manufacturing subsidiary is located. The milestone clears an important manufacturing...

Read more

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

September 8, 2026 10:20 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that it has entered into an agreement with Curia Global, Inc. ("Curia"), a global leader in contract manufacturing, to initiate technology The agreement represents the next major step in advancing eXoZymes' proprietary NCT manufacturing process from successful...

Read more

RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements

September 8, 2026 7:02 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that its RMTG's Cellgenic division has commenced local commercial arrangements in Colombia, including steps to establish local representation and to develop relationships with physicians and medical providers in permitted channels. The Colombia...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

September 7, 2026 11:45 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer...

Read more

Faron Pharmaceuticals Ltd: Holding(s) In Company

September 4, 2026 6:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares: Faron Pharmaceuticals Oy 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer X 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of...

Read more

USDA Deregulates Darling 54 After Six-Year Federal Review

September 3, 2026 1:45 PM

American Chestnut Restoration, Inc. (ACR), a 501(c)(3) nonprofit, volunteer-run organization dedicated to restoring the American chestnut, welcomes the U.S. Department of Agriculture's (USDA) decision to deregulate Darling 54, a blight-tolerant American chestnut developed and tested over decades. The decision follows extensive laboratory and field research, USDA review beginning in January 2020, nationwide public comments, detailed plant pest...

Read more

Cellgenic Establishes Local Commercial Presence in Brazil

September 3, 2026 7:01 AM

Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that its Cellgenic division has expanded its commercial presence in Brazil through local representation, physician-facing commercial support, and related infrastructure intended to support product distribution in permitted channels. Brazil is an...

Read more

Synexis, LLC and Zee Company Partner to Advance Food Safety Through Proactive, Continuous Pathogen Control

September 2, 2026 11:50 AM

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, today announced a strategic collaboration with Zee Company, a member of the Vincit Group, one of the nation's leading providers of food safety, sanitation, and intervention solutions serving food and beverage manufacturers throughout the United States. Together, the companies will expand access to Synexis' patented DHP® technology to food and beverage processing...

Read more

Ayrmid Appoints Ideogen for Omisirge(R) in EMEA

September 1, 2026 8:00 AM

Ayrmid Ltd. ("Ayrmid" or the "Company"), parent company of Gamida Cell Inc., today announced the appointment of Ideogen Group GmbH ("Ideogen") as its exclusive distributor for Omisirge® (omidubicel-onlv). Under the agreement, Ideogen is granted exclusive rights to launch a managed access program for Omisirge across 55 markets in Europe (excluding Greece and Cyprus), the Middle East and North Africa (MENA), and the Commonwealth of Independent...

Read more

RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint

September 1, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the commencement of Cellgenic commercial activity in Peru through the establishment of local commercial arrangements, including exclusive representation arrangements in permitted channels. The Peru announcement extends Cellgenic's Latin American...

Read more

Vicore Pharma to Participate in Upcoming Healthcare Conferences

September 1, 2026 2:20 AM

Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following upcoming healthcare conferences: Wells Fargo Healthcare Conference Location: Encore Boston Harbor, Boston, Mass. Format: 1×1 meetings Participation Date: Tuesday, September 8, 2026...

Read more

Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement

August 31, 2026 7:00 PM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce closing of the second tranche of its previously announced non-brokered private placement offering of common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share (the "Private...

Read more

USDA Deregulates The Darling 54 American Chestnut

August 31, 2026 9:00 AM

SilvaBio is proud to announce that the U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) have formally deregulated the Darling 54 American chestnut-a landmark achievement in a decades-long effort to restore this species to its 25-state native range. Photo credit John Carnessali Following a thorough, multi-year review process, the agency has determined that the modified American chestnut developed at the...

Read more

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

August 28, 2026 7:00 PM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce an upsize to its previously announced non-brokered private placement offering of common shares in the capital of the Company ("CommonShares") at a price of $0.085 per Common Share (the "Private Placement"). The...

Read more

Lobe Sciences Expands Leadership Team with New CFO Appointment

August 28, 2026 8:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing differentiated therapeutics for serious conditions with significant unmet medical needs, today announced the appointment of Dr. David Kideckel, Ph.D., MBA, as Chief Financial Officer, effective September 1, 2026. "We are pleased to welcome David to Lobe's executive leadership team at an important stage in the...

Read more